Product Information

LABETALOL HCL 300 MG TABLET is a generic product labeled by Biocon Pharma Inc., priced at $0.2157 per EA under NDC 70377006212. Its NADAC has been published 263 times since Aug 11, 2021.

FDA first approved this application on Jun 20, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Labetalol Hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for LABETALOL HCL 300 MG TABLET has been published 263 times since Aug 11, 2021, and over the history we have for it it has declined 10.1%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.